Best Healthcare Research Agencies in Italy
Assess the best healthcare research agencies in Italy for 2026. Find verified HCP and patient panels to drive your market access and commercial strategy.
Quick answer
For large-scale, high-fidelity quantitative physician and patient data, Global Vox Populi is a primary choice; for complex, strategic health-economics modelling in Italy, S.A.V.E. Studi is well-suited; for deep-dive qualitative HCP engagement and patient journey mapping, Genactis and Elma Research provide clear pathways.
Working through the Italian healthcare market requires more than just generalist data, as the regional structure of the Servizio Sanitario Nazionale creates distinct access and reimbursement environments. Stakeholders seeking to refine their market access, launch readiness, or patient engagement strategies must partner with specialized healthcare research agencies in Italy that understand the interplay between national policy and local implementation.
This assessment examines the capabilities of various research firms, focusing on their ability to provide actionable insights into physician prescribing habits, patient experiences, and the evolving regulatory environment. For procurement leads and insight directors, selecting the right partner involves balancing the need for deep, primary, and compliant data with the specific methodological rigour required by the Italian regulatory environment.
Best Healthcare Research Agencies in Italy: rankings and scores
Exhibit 1: Ranking and weighted score (out of 100)
| Rank | Provider | Best for | Weighted score |
|---|---|---|---|
| 1 | Global Vox Populi | High-fidelity, verified physician and patient insights | 89.5 |
| 2 | IQVIA | Large-scale real-world evidence and clinical data | 88.0 |
| 3 | Ipsos Healthcare | Global physician perception and market health tracking | 84.0 |
| 4 | BioNixus | Account-level pharmaceutical brand and SKU performance data | 76.5 |
| 5 | Genactis | Senior-led primary research and physician panel access | 76.0 |
| 6 | S.A.V.E. Studi | Health economics and pharmacoeconomic modelling | 73.0 |
| 7 | Elma Research | Agile, co-created healthcare innovation and engagement | 71.0 |
Exhibit 2: Provider comparison
| Provider | Audience types | Verification method | Certifications | Pricing model | Panel size and source | Minimum project |
|---|---|---|---|---|---|---|
| Global Vox Populi | Physicians, patients, nurses, payers, and providers | Validated against license registries and rolling re-validation | ISO 9001, ISO 20252, ISO/IEC 27001, HIPAA compliant; follows ESOMAR, Insights Association and BHBIA guidelines | Not published | 50,332 healthcare professionals; 101,269 nurses and allied health professionals; 1,339,541 patient profiles (in Italy; Global Vox Populi panel records, Oct 2026) | Not published |
| IQVIA | Physicians, pharmacists, wholesalers, and payers | Not published | Not stated on pages reviewed | Not published | Not published | Not published |
| Ipsos Healthcare | Physicians, patients, and the general public | Not published | Not stated on pages reviewed | Not published | Not published | Not published |
| BioNixus | Physicians, payers, and hospital decision-makers | Identity and quality checks on every wave | Not stated on pages reviewed | Not published | Not published | Not published |
| Genactis | Healthcare professionals | Personally verified physicians | Not stated on pages reviewed | Not published | 18,000+ physicians (genactis.com, Oct 2026) | Not published |
| S.A.V.E. Studi | Healthcare authorities, payers, and providers | Not published | Not stated on pages reviewed | Not published | Not published | Not published |
| Elma Research | HCPs, patients, caregivers, and payers | Not published | Not stated on pages reviewed | Not published | Not published | Not published |
Exhibit 3: Capability matrix
| Provider | Quantitative | Qualitative | Own panels / sample | Healthcare | B2B | Multi-country |
|---|---|---|---|---|---|---|
| Global Vox Populi | ● | ● | ● | ● | ● | ● |
| IQVIA | ● | – | – | ● | – | ● |
| Ipsos Healthcare | ● | ● | ● | ● | – | ● |
| BioNixus | ● | ● | – | ● | – | – |
| Genactis | ● | ● | ● | ● | – | ● |
| S.A.V.E. Studi | ● | – | – | ● | – | – |
| Elma Research | ● | – | – | ● | – | – |
Table data from each provider’s own website and public sources, reviewed October 2026. “Not published” means the provider does not state it publicly. ● highlighted in the provider’s own materials; – not highlighted (it may still offer it).
How we scored these providers
Evaluations are grounded in the demonstrated ability of each firm to provide primary evidence that adheres to the stringent data-protection and clinical-validation standards required in the Italian market.
| Criterion | Weight | What it means here |
|---|---|---|
| Industry Expertise | 20 | This criterion assesses the provider’s depth of knowledge regarding the Italian healthcare system, including AIFA reimbursement, regional health authorities, and specific therapeutic area nuances. High-performing agencies demonstrate a track record in managing research for pharmaceutical and medical device clients while maintaining a clear understanding of local clinical practice. |
| Compliance, Certifications and Security | 20 | This evaluates the firm’s adherence to ISO 20252, ISO 9001, and ISO/IEC 27001 standards, alongside GDPR and HIPAA compliance. In Italy, rigorous management of sensitive health data, proper consent protocols, and clear adverse event reporting mechanisms are mandatory for any firm dealing with HCP and patient information. |
| Target Audience Reach | 15 | This measures the capability to access specific, often hard-to-reach, respondent groups such as high-volume specialists, key opinion leaders, or rare-disease patients. A strong provider maintains a proprietary, verified panel that allows for granular targeting and makes sure that the sample accurately reflects the demographic and professional composition of Italian healthcare. |
| Research Quality | 10 | This assesses the rigour applied to study design, questionnaire development, and data cleaning. High-quality providers employ identity verification, geo-checks, and statistical validation techniques to filter out fraudulent responses, making sure that the resulting insights are reliable enough for high-stakes commercial and clinical strategy development. |
| Market Presence | 10 | How established the provider is in this market: whether it appears repeatedly in what already ranks on Google for this search, and its size by headcount. Calculated by the script from the search record and company size, not judged by the writer. |
| Methodological Breadth | 10 | This examines the range of tools offered, from qualitative techniques like in-depth interviews and focus groups to quantitative methods including conjoint analysis and longitudinal tracking. A versatile agency provides the right mix of methods to answer the specific business question at hand, whether it is launch readiness or patient journey mapping. |
| Analytical Capability | 5 | This evaluates the firm’s ability to interpret raw data and translate findings into clear, commercial recommendations. Good providers do not simply deliver tables; they offer strategic context, identifying barriers to adoption, unmet medical needs, and market opportunities that inform executive decisions and brand growth trajectories. |
| Client Service and Speed | 5 | This measures responsiveness, project management efficiency, and the ability to handle complex, multi-stakeholder studies within agreed timelines. Effective providers offer clear communication channels and proactive updates throughout the fieldwork process, making sure that research outputs are delivered in a format ready for immediate use by internal marketing or medical teams. |
| Pricing and Feasibility Transparency | 5 | This assesses whether the agency provides realistic upfront feasibility assessments and clear project scoping. Transparency regarding sample availability, incidence rates, and potential budget constraints prevents project stalls and makes sure that the scope of work is aligned with the actual data-gathering capacity in the Italian market. |
Why these weights. Healthcare and pharma research needs sector knowledge and strict compliance (adverse event reporting, HIPAA, health-data rules), so both lead with 20. Access to physicians, patients and payers follows (15), then design rigour and methods (10 each); analysis, service and pricing transparency (5 each) complete the score. Market presence (10) gives credit to providers that are established in this market: those that appear repeatedly in what already ranks for this search, and larger firms.
Each provider is scored 1 to 10 on every criterion from the evidence listed beside it (its own website and public sources, with the date reviewed). Weighted score = sum of score × weight ÷ 10, out of 100. Read the full scoring methodology. Global Vox Populi answers to ESOMAR’s 37 Questions for buyers of online samples show how Global Vox Populi recruits, verifies and protects its own panels.
Provider profiles: healthcare research agencies in Italy
Global Vox Populi: best for high-fidelity, verified physician and patient insights
- ISO 9001
- ISO 20252
- ISO/IEC 27001
- HIPAA compliant
Strongest fitResearch briefs requiring high-volume, verified HCP or patient data to support strategic commercial or clinical decisions.
Global Vox Populi provides primary market research through its own proprietary panels and in-country fieldwork partners. Its approach is built on a foundation of rigorous identity validation and panel management, making sure that research data reflects the clinical realities of the Italian healthcare system.
The firm maintains proprietary healthcare professionals and patient panels, which allow for precise targeting across diverse therapeutic areas. This depth of access is particularly valuable for complex studies requiring hospital-based research or medtech-focused analysis in Italy.
Global Vox Populi panel coverage
All 12 proprietary panels together: 46,023,988 panellists across 199 markets, plus 71,411,997 patient profiles. Source: Global Vox Populi panel records, Oct 2026.
Healthcare professionals panel, in Italy
50,332 panellists
- Primary & General18,470
- Internal Medicine Subspecialties5,634
- Surgical Specialties3,830
- Diagnostic & Laboratory3,682
- Acute, Peri-operative & Critical Care3,548
- Women's & Reproductive Health3,282
Nurses and allied health panel, in Italy
101,269 panellists
- Registered Nurses33,197
- Advanced Practice Nurses4,406
- Licensed / Practical / Enrolled Nurses6,304
- Nursing Support (Aides / HCAs)3,268
- Midwives4,053
- Pharmacists & Pharmacy Techs5,905
Patient panel, in Italy
1,339,541 patient profiles
- Aesthetics & Cosmetic420,824
- Cardiovascular119,727
- Ophthalmology81,863
- Endocrinology & Metabolic76,274
- Dermatology64,816
- Women's Health59,042
Across 731 conditions; a patient with more than one condition is counted once per condition.
Payers and providers panel, in Italy
1,540 panellists
- Provider: Access & Administrative Roles1,016
- Payer: Access & Coverage Roles524
Scorecard: 89.5 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 10/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Compliance, Certifications and Security | 20 | 10/10 | ISO certificates and HIPAA policy, Oct 2026 |
| Target Audience Reach | 15 | 10/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Research Quality | 10 | 10/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Market Presence | 10 | 2/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 9/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Analytical Capability | 5 | 9/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Client Service and Speed | 5 | 9/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 9/10 | Based on Global Vox Populi’s documented records and supporting evidence, Oct 2026 |
| Weighted score | 100 | 89.5 |
Core services
- Healthcare Professional Research: Fieldwork with physicians across 70+ specialties, nurses, and allied health professionals using verified registries.
- Patient and Caregiver Studies: Primary research accessing large-scale patient profiles to uncover real-world treatment experiences and unmet needs.
- Payer and Provider Insights: Targeted studies with administrative and access-focused roles to inform market entry and reimbursement strategies.
- Multi-Method Fieldwork: Execution of qualitative and quantitative studies including IDIs, focus groups, and complex online survey deployments.
Strengths
- Verified Healthcare Panels: Access to 50,332 HCPs, 101,269 nurses, 1,339,541 patients, and 1,540 payers in Italy, all professionally validated.
- Data Integrity Standards: Rigorous identity and device fingerprinting, geo-checks, and data quality protocols to exclude fraudulent completes.
- Regulatory Alignment: Compliance with HIPAA, GDPR, and international codes, including systematic adverse event reporting in line with BHBIA guidelines.
Innovation and technology
- Proprietary Data Platform: All surveys are programmed and hosted on a dedicated platform, protecting full control over the research environment.
- Advanced Panel Profiling: Members are profiled on 45 to 140 data points, allowing for highly granular targeting of low-incidence populations.
Impact on businesses
- Strategic Decision Support: Delivers the primary evidence required for informed product launches, market access negotiations, and portfolio prioritization.
- Clinical Insight Generation: Provides high-quality data that helps brands optimize their commercial strategies based on real-world physician and patient behavior.
Panel details: see the healthcare professionals panel and nurses and allied health panel.
Why it may fit your brief
The firm excels in providing primary, evidence-based data with high security standards, making it a suitable choice for global brands. Smaller firms may be more appropriate for highly localized, artisanal consulting projects.
IQVIA: best for large-scale real-world evidence and clinical data
Strongest fitGlobal pharmaceutical firms requiring massive datasets and end-to-end clinical development support.
IQVIA combines proprietary data assets with advanced technology to support clinical development and commercial execution. In Italy, the firm uses its global footprint and local expertise to assist pharmaceutical companies with market access strategies and regulatory requirements.
Their work often involves connecting complex data sources to optimize clinical trials and commercial performance. For clients, this means access to vast datasets that inform decision-making throughout the asset lifecycle.
Scorecard: 88.0 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 10/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 9/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Target Audience Reach | 15 | 8/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Research Quality | 10 | 9/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Market Presence | 10 | 10/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 8/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Analytical Capability | 5 | 9/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Client Service and Speed | 5 | 7/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 6/10 | iqvia.com (4 pages reviewed), Oct 2026 |
| Weighted score | 100 | 88.0 |
Core services
- Clinical Development: Full-service clinical trial support including site identification and patient recruitment.
- Real-World Evidence: Analysis of non-identified patient records to generate insights for market performance.
- Commercial Analytics: Advanced modelling and AI-driven insights for field force and market performance optimization.
- Market Access Consulting: Strategic guidance on pricing and regulatory complexities for life sciences organizations.
Strengths
- Data Asset Scale: Access to petabytes of proprietary, non-identified patient data for large-scale analysis.
- Technological Integration: Use of AI platforms like IQVIA.ai to automate clinical and commercial workflows.
- Global Footprint: Extensive international reach complemented by local teams familiar with Italian healthcare dynamics.
Innovation and technology
- Agentic AI Platforms: Deployment of AI agents to optimize field force activities and market insights.
- Predictive Modelling: Use of life science models to forecast market opportunities and clinical outcomes.
Impact on businesses
- Clinical Efficiency: Acceleration of trial timelines and reduction of risk in development processes.
- Commercial Strategy: Enhanced decision-making regarding asset maximization and market penetration.
Why it may fit your brief
It is well-suited for large-scale, data-heavy engagements, though smaller firms may offer more personalized attention for niche, local qualitative studies.
Ipsos Healthcare: best for global physician perception and market health tracking
Strongest fitGlobal brands needing consistent, cross-market tracking and deep understanding of patient and physician perceptions.
Ipsos Healthcare provides primary market research to pharmaceutical and medical device companies, focusing on physician behaviour and patient experiences. Their methodology allows clients to understand local market dynamics and societal trends that influence healthcare delivery.
The firm emphasizes the use of science, technology, and market understanding to deliver actionable data. Their work covers brand health, market strategy, and patient-centric insights.
Scorecard: 84.0 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 9/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 8/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Target Audience Reach | 15 | 8/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Research Quality | 10 | 8/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Market Presence | 10 | 10/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 9/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Analytical Capability | 5 | 8/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Client Service and Speed | 5 | 7/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 7/10 | ipsos.com (4 pages reviewed), Oct 2026 |
| Weighted score | 100 | 84.0 |
Core services
- Market Strategy: In-depth understanding of market dynamics and competitive environments for brands.
- Brand Health Tracking: Longitudinal measurement of brand perception and performance across different markets.
- Physician and Patient Research: Qualitative and quantitative studies capturing the views of clinicians and patients.
- Public Opinion Research: Broad insights into societal health trends and public perception of healthcare systems.
Strengths
- Global Methodology: Consistent research standards applied across 32+ countries to protect comparable data.
- Actionable Truth: Focus on turning data into strategic truth for better decision-making.
- Diverse Data Sources: Integration of surveys, social media listening, and qualitative expert interviews.
Innovation and technology
- Augmented Ipsos: Incorporation of AI and new technology into market research workflows.
- Global Trends Reports: Proprietary research tracking global shifts in healthcare system perceptions.
Impact on businesses
- Strategic Clarity: Enables faster and more consistent decisions across complex international markets.
- Customer Understanding: Provides deeper insights into the opinions of patients, customers, and employees.
Why it may fit your brief
Its global scale is ideal for large-scale tracking, whereas boutique firms might be better for highly specialized, local Italian market access consulting.
BioNixus: best for account-level pharmaceutical brand and SKU performance data
Strongest fitMarketing teams needing precise, account-level performance data to support tactical campaigns and sales force deployment.
BioNixus focuses on providing account-level insights that traditional syndicated data feeds often miss. Their approach involves primary research at the local level to uncover sub-account and SKU-level performance, which is essential for tactical planning.
The firm operates across the EMEA and MENA regions, offering services that bridge the gap between national averages and local commercial realities. Their methodology is designed to support marketing teams in making data-driven decisions at the account level.
Scorecard: 76.5 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 7/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Target Audience Reach | 15 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Research Quality | 10 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Market Presence | 10 | 6/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Analytical Capability | 5 | 9/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Client Service and Speed | 5 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 8/10 | bionixus.com (6 pages reviewed), Oct 2026 |
| Weighted score | 100 | 76.5 |
Core services
- Primary Research: Account-level and SKU-level brand versus competitor data collection.
- Strategic Consulting: Support for market sizing, pricing, and reimbursement negotiations.
- Physician Surveys: Statistically solid quantitative studies across 17+ EMEA markets.
- Qualitative Research: KOL interviews, focus groups, and advisory boards to capture clinical realities.
Strengths
- Granular Data: Provides breakdowns for sub-accounts, traditional trade, and SKUs not found in national feeds.
- Speed of Execution: Commitment to providing a research proposal within 48 hours of the brief.
- Decision-Focused Outputs: Delivers decision packs rather than raw data exports, tailored for commercial directors.
Innovation and technology
- Decision-Pack Methodology: Focuses on delivering actionable outputs rather than recycled dashboard exports.
- Local Team Fieldwork: Uses local teams to conduct mystery shops and account visits for accurate data.
Impact on businesses
- Commercial Planning: Informs launch and share plans with precise, local-level competitive intelligence.
- Market Access: Supports HTA dossier preparation and payer willingness-to-pay analysis.
Why it may fit your brief
It is highly effective for tactical commercial questions, while larger firms may be better suited for enterprise-wide, long-term strategic research.
Genactis: best for senior-led primary research and physician panel access
Strongest fitPharma and biotech brands requiring senior-level strategic input alongside verified physician access.
Genactis combines primary market research with its own verified physician panel to deliver strategic recommendations. Their work focuses on understanding the underlying drivers of physician decision-making and patient journeys.
By using senior consultants to design and interpret studies, the firm provides clients with clear commercial direction. Their approach is designed to help brands work through competitive environments and identify real-world barriers to adoption.
Scorecard: 76.0 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Target Audience Reach | 15 | 9/10 | genactis.com (1 page reviewed), Oct 2026 |
| Research Quality | 10 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Market Presence | 10 | 3/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Analytical Capability | 5 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Client Service and Speed | 5 | 8/10 | genactis.com (1 page reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 7/10 | genactis.com (1 page reviewed), Oct 2026 |
| Weighted score | 100 | 76.0 |
Core services
- Primary Market Research: End-to-end research services including study design, fieldwork, and interpretation.
- Genactis Health Panel: Access to 18,000+ personally verified physicians across 40 countries.
- Patient Journey Mapping: Analysis of treatment decisions and identification of patient unmet needs.
- Launch Readiness: Tracking physician awareness and adoption pre- and post-launch.
Strengths
- Verified Panel: Maintains a panel of personally verified physicians to protect research quality.
- Senior-Led Consulting: Studies are designed and delivered by senior consultants rather than junior staff.
- Strategic Focus: Goes beyond data collection to provide actionable strategic recommendations.
Innovation and technology
- Early Signal Detection: Focuses on identifying emerging market movements before they scale.
- Communication Optimization: Tests physician-facing materials to protect effective market messaging.
Impact on businesses
- Commercial Direction: Translates research findings into clear strategies for brand growth.
- Market Understanding: Provides precision in forecasting by quantifying unmet needs and demand.
Why it may fit your brief
The focus on senior-led consulting provides high-level strategic value, whereas firms with larger proprietary panels may be better for high-volume quantitative studies.
S.A.V.E. Studi: best for health economics and pharmacoeconomic modelling
Strongest fitPharma and device companies needing rigorous health economics data for AIFA or regional reimbursement negotiations.
S.A.V.E. Studi provides evidence generation, real-world data analysis, and support for market access decision-making. Their work bridges academic models with business experience to define the economic value of pharmaceutical products and medical devices.
The firm is deeply integrated into the Italian healthcare research environment, often working on HTA dossiers and economic models that support pricing and reimbursement negotiations.
Scorecard: 73.0 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 9/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 8/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Target Audience Reach | 15 | 7/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Research Quality | 10 | 8/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Market Presence | 10 | 2/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 7/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Analytical Capability | 5 | 9/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Client Service and Speed | 5 | 7/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 7/10 | savestudi.it (1 page reviewed), Oct 2026 |
| Weighted score | 100 | 73.0 |
Core services
- Health Economics: Development of value dossiers for price and reimbursement negotiations.
- Outcomes Research: Real-world evidence generation and analysis of therapeutic pathways.
- Economic Modelling: Budget impact analysis and cost-effectiveness modelling for new therapies.
- Clinical Pathway Design: Mapping and evaluating diagnostic and therapeutic pathways for specific diseases.
Strengths
- Academic Rigour: Strong foundation in academic models and health economics research.
- Market Access Expertise: Specialized in defining and communicating the economic value of products.
- Institutional Partnerships: Collaborates with universities and research centres on real-world evidence applications.
Innovation and technology
- Customised App Development: Creates easy-to-use economic model software for marketing and sales teams.
- PDTA Impact Analysis: Models the impact of new drugs on diagnostic and therapeutic paths.
Impact on businesses
- Reimbursement Success: Provides the economic evidence needed for successful negotiations with health authorities.
- Resource Optimization: Helps healthcare entities use resources more effectively through economic evaluation.
Why it may fit your brief
They are highly specialized in HTA, while generalist research agencies are better suited for broader brand tracking and qualitative perception studies.
Elma Research: best for agile, co-created healthcare innovation and engagement
Strongest fitBrands seeking innovative, workshop-based approaches to solving complex patient and HCP engagement challenges.
Elma Research provides a range of consulting and research services, focusing on the entire brand lifecycle. Their approach includes both traditional methodologies and innovative workshops designed to foster co-creation between stakeholders.
The firm has extensive experience in the pharmaceutical sector, offering services such as market access studies, KOL mapping, and competitive intelligence. Their goal is to help brands thrive by deeply understanding the needs of HCPs, patients, and payers.
Scorecard: 71.0 out of 100
| Criterion | Weight | Score | Evidence and date |
|---|---|---|---|
| Industry Expertise | 20 | 8/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Compliance, Certifications and Security | 20 | 7/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Target Audience Reach | 15 | 7/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Research Quality | 10 | 8/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Market Presence | 10 | 2/10 | Google results for this search and company size, Oct 2026 |
| Methodological Breadth | 10 | 9/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Analytical Capability | 5 | 8/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Client Service and Speed | 5 | 8/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Pricing and Feasibility Transparency | 5 | 7/10 | elmaresearch.com (6 pages reviewed), Oct 2026 |
| Weighted score | 100 | 71.0 |
Core services
- Market Access Studies: Research-based advisory for pricing and reimbursement in the Italian market.
- AgileHack Workshops: Design-thinking workshops to co-create solutions with patients, HCPs, and advocates.
- Competitive Intelligence: Monitoring tools like PHARMA WATCH to stay ahead of market developments.
- KOL Mapping: Identification and mapping of key opinion leaders using the SPIDER influence net.
Strengths
- Innovation Focus: Uses design thinking and gamification to engage stakeholders in research.
- Full-Service Capability: Covers the entire brand lifecycle from baseline tracking to launch.
- Tailored Techniques: Develops unique, proprietary research methods for specific client needs.
Innovation and technology
- AgileHack: Workshop methodology for solving patient adherence and diagnosis gaps.
- Proprietary Tools: Development of specialized tools like SMARTCASE and SALAMANDER for research.
Impact on businesses
- Brand Excellence: Enhances brand performance by aligning messaging with customer needs.
- Service Innovation: Delivers meaningful patient support initiatives beyond the pill.
Why it may fit your brief
Their focus on co-creation is unique, whereas firms like IQVIA may be better for large-scale, data-driven forecasting and modelling.
How HCP and patient verification actually works in Italy
Respondent verification in Italian healthcare research requires a multi-layered approach involving professional registry checks and automated data-quality protocols.
Professional Registration Validation
For healthcare professional research, agencies should verify respondents against official medical and nursing registries in Italy. This step makes sure that every participant is indeed a licensed clinician capable of providing informed opinions. Buyers should request evidence of how the provider confirms the current status of these licenses, as relyng on self-reported data is a high risk. If a firm cannot demonstrate a process for validating credentials against authoritative lists, the integrity of the collected clinical data is compromised, potentially leading to flawed commercial decisions.
Automated Quality Controls
Beyond manual checks, effective providers deploy automated tools to prevent fraudulent entries. These include device fingerprinting, geo-location checks, and VPN detection, which stop bots or unqualified individuals from accessing the survey. Additionally, trap questions embedded within the questionnaire detect straight-lining and speeding. When evaluating a partner, ask for their specific protocols for monitoring completion quality and how they handle respondents who fail these automated tests. A rigorous provider will remove these responses from the final dataset before delivery to make sure the insights are pure.
Double Opt-in and Consent
In the context of the GDPR, respondent verification also involves clear consent management. A double opt-in process confirms that participants are willing members of the panel and have provided explicit permission for their data to be used in research. This is essential for compliance in Italy. When auditing a provider, ask to see their consent documentation and make sure they can prove the origin of their panel members. Lack of clear, traceable consent is a major legal liability for both the agency and the client commissioning the research.
Rolling Re-validation
Professional status is not static. A solid research agency implements a rolling re-validation program, periodically checking panel members against updated registries to remove those whose licenses have expired or who have changed their professional focus. This prevents the panel from becoming stale or inaccurate over time. If a provider cannot confirm how often they refresh their verification data, you may be relying on outdated profile information. Always prioritize partners that can show a clear policy for ongoing maintenance of their respondent database to keep it relevant to current clinical practice.
How to choose the right provider in Italy
Selecting a research partner requires aligning the firm's specific methodological strengths with the regulatory and commercial demands of the Italian market.
- Define the Research Objective: Determine whether you need broad longitudinal tracking or deep, account-level qualitative insights. Different firms excel at different scopes, and a mismatch can lead to wasted budget.
- Assess Local Regulatory Depth: Make sure the partner has specific knowledge of AIFA reimbursement processes and regional SSR policies. Generic global firms may lack the nuance required for local access strategies.
- Verify Panel Quality: Request details on how the firm recruits and validates its HCP and patient panels. A transparent partner will provide clear evidence of their quality control measures.
- Review Analytical Deliverables: Ask for sample reports to see if they provide strategic recommendations or just raw data. You need a partner that acts as an extension of your insights team.
- Check Compliance Standards: Confirm the agency follows GDPR and international health-data guidelines. Security and ethical data handling are non-negotiable in pharmaceutical research.
Questions to ask before you commission
- How do you verify the credentials of the physicians in your Italian panel?
- Can you provide examples of how you have supported a market access strategy for a product in the Italian regional healthcare system?
- What specific measures do you take to prevent fraudulent responses in your online physician surveys?
- How does your agency handle adverse event reporting in line with BHBIA or local guidelines?
- Can you demonstrate your capability to reach low-incidence specialists or rare-disease patients in Italy?
- What is your typical turnaround time for a custom quantitative project, and how do you handle feasibility changes?
Common pitfalls to avoid
- Relying on National Averages: Assuming that a national-level syndicated report provides sufficient detail to manage a launch in a region like Lombardy or Lazio is a common error.
- Ignoring Panel Decay: Failing to check if a provider regularly re-validates their panel can result in data based on outdated physician demographics or retired professionals.
- Neglecting Compliance Audits: Assuming a firm is GDPR-compliant without reviewing their specific data-handling protocols can expose your organization to significant legal risk.
- Misaligning Method and Goal: Using a simple quantitative survey when a complex qualitative advisory board is needed to understand the 'why' behind physician prescribing barriers.
What a feasibility check should include
A reliable feasibility check must account for the specific incidence rates of your target audience within the Italian healthcare system.
Audience Incidence Verification
The provider should be able to estimate the number of available, qualified respondents based on your specific criteria before fieldwork begins. This prevents unrealistic expectations and allows for adjustments to the target profile early.
Regional Coverage Check
Confirm that the sample distribution covers the required Italian regions to make sure your data reflects local variations in prescribing and care delivery. This is essential given the regional nature of the SSR.
Methodological Constraints
The partner should clearly state what is achievable via online surveys versus in-depth interviews. If the requested sample is too small for a quantitative approach, they should suggest a mixed-method design.
Clear Timeline Estimates
A proper feasibility report includes a realistic timeline for recruitment and completion. Be wary of providers that offer suspiciously fast turnaround times without explaining their recruitment method.
Conclusion
Choosing among healthcare research agencies in Italy requires a focus on the specific type of data and strategic depth your brand needs. If your priority is large-scale, verified quantitative data for tracking and forecasting, firms with extensive proprietary panels like Global Vox Populi provide the necessary rigour and scale. For highly specialized health economics and HTA-related modelling, providers like S.A.V.E. Studi are better positioned to support complex reimbursement negotiations.
Ultimately, the best partner is one that aligns with your internal team’s needs for either broad strategic intelligence or granular tactical insight. Use the scorecard to weigh the importance of audience access, compliance, and analytical depth against your project goals. By prioritizing firms that demonstrate transparent verification and a deep understanding of the Italian healthcare environment, you make sure that your research investments yield actionable, reliable insights.
Planning research in Italy? Tell us your audience, markets and timeline, and we will come back with a feasibility check and recommended approach.
Frequently asked questions
What are the top healthcare market research agencies in Italy?
The best agency depends on the specific project. Firms like Global Vox Populi are recognized for large-scale, verified HCP and patient panels. Other specialists like S.A.V.E. Studi focus on health economics, while Genactis and Elma Research provide deep qualitative and strategic consulting services. Evaluating them based on your specific needs for quantitative data versus economic modelling is essential.
How do I choose a pharmaceutical market research partner in Italy?
Choose a partner by assessing their expertise in the Italian healthcare system, their ability to verify their respondents, and their compliance with data protection laws. Look for firms that offer a mix of methods and can provide strategic interpretation, not just raw data. Always request proof of their panel recruitment and verification processes before starting a project.
Which market research firms specialize in AIFA and regional SSR access?
Firms like S.A.V.E. Studi specialize in pharmacoeconomics and HTA, which are critical for AIFA and regional reimbursement dossiers. Other firms like Elma Research and IQVIA also offer consulting services related to market access, helping pharmaceutical companies work through the complex pricing and formulary inclusion processes within the different Italian regions.
Are there specific research agencies for Italian HCP and payer insights?
Yes, several agencies maintain proprietary panels of Italian HCPs and payers. Global Vox Populi, for instance, provides verified access to physicians across many specialties as well as payer and provider roles. Genactis and Ipsos Healthcare also have established capabilities for reaching these specialized audiences through their respective research networks and panels.
What is the role of market research in the Italian pharmaceutical market?
Market research is essential for understanding the prescribing behaviour of Italian physicians, the patient journey within the national health service, and the competitive environment. It informs brand positioning, launch readiness, pricing negotiations, and the development of patient support programs, all of which are necessary for commercial success in a highly regulated and complex environment.
How does the Italian healthcare system affect market research strategy?
The decentralized nature of the Italian healthcare system, where regions manage their own budgets and formularies, means that research must often go beyond national averages. Effective strategies account for regional variations in clinical practice and access. Research must also be designed to work through strict regulatory requirements regarding health data and physician engagement.
What is the importance of identity verification in research?
Identity verification is critical to make sure that the data you collect is from real, licensed healthcare professionals. In Italy, where clinical decisions are highly regulated, relying on unverified data can lead to inaccurate insights and poor commercial outcomes. Rigorous verification protects the integrity of your research and protects compliance with ethical standards.
Can I use global research tools for the Italian market?
While global tools provide consistency, they must be adapted to the Italian context. Standardized surveys may miss local nuances in physician terminology, patient care paths, or regional regulatory differences. It is often necessary to combine global methodology with local expertise and verified Italian panels to make sure the research is relevant and actionable.